<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081480</url>
  </required_header>
  <id_info>
    <org_study_id>VALID2</org_study_id>
    <nct_id>NCT04081480</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Valacyclovir Oral Solution in Children</brief_title>
  <acronym>VALID2</acronym>
  <official_title>Pharmacokinetics of a New Paediatric Formulation of Valacyclovir Used for Prophylaxis and Treatment of Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) Infections in Children, Phase II (VALID II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Valacyclovir has replaced acyclovir in many clinical scenarios. Pharmacokinetic data support
      the use of oral valacyclovir in children, but practical problems exist in children having to
      take adult-dose tablets. A formulation with acceptable palatability, good pharmaceutical
      quality and possibility of flexible dosing is developed. Pharmacokinetic data of this
      formulation is missing.

      The present study investigates the pharmacokinetics of valacyclovir oral solution in children
      by determine the area under the curve (AUC0-12), time above critical concentration (Ccrit),
      Cmax and Tmax of acyclovir.

      Secondary, the safety profile of a single dose of valacyclovir oral solution will be
      determined.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Intervention is pharmacokinetic (PK) curve collection in children, two age groups</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>12 hours</time_frame>
    <description>Acyclovir area under the curve (12h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>12 hours</time_frame>
    <description>Maximum concentration of aciclovir</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>12 hours</time_frame>
    <description>Time to reach maximum concentration of aciclovir</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>1 day</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Herpes Simplex Virus Infection</condition>
  <condition>Varicella Zoster Virus Infection</condition>
  <arm_group>
    <arm_group_label>Valacyclovir oral solution</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Valacyclovir oral solution as administered in standard of care. Dosage: 10 mg/kg BID for children weighing less than 40 kg and 500 mg BID for children weighing 40 kg or more.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <description>PK curve collection to determine acyclovir exposure after administration of valacyclovir oral solution</description>
    <arm_group_label>Valacyclovir oral solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is in the age of 2-12 years.

          -  Subject has an indication for (val)acyclovir prophylaxis and are planned to receive
             valacyclovir oral solution.

          -  Subject is managed with a central venous catheter (CVC/Port-a-Cath).

          -  Subject's parents have signed the Informed Consent Form prior to screening
             evaluations.

          -  Subject is willing to participate after study procedures are explained in
             comprehensible language for the child.

        Exclusion Criteria:

          -  Severe anemia (&lt;6.0 mmol/L).

          -  Full dose has not been taken.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>D Burger</last_name>
    <phone>+31243611111</phone>
    <email>david.burger@radboudumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prinses Maxima Centrum voor kinderoncologie</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C. Lindemans</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Varicella Zoster Virus Infection</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

